Skip to main content

Table 1 Demographic and clinical characteristics of deceased donors and recipients

From: Excellent clinical outcomes of renal transplant from pediatric deceased donors with acute kidney injury

 

Pediatric donor cohort

p-value

Adult donor cohort

p-value

AKI group (n = 41)

Non-AKI group (n = 113)

AKI group (n = 218)

Non-AKI group (n = 368)

Donor

      

 Age, years, mean (SD)

9.70 ± 5.43

7.11 ± 5.56

0.006

46.29 ± 11.71

48.21 ± 11.51

0.067

 Male, n (%)

25 (61.0)

77 (68.1)

0.406

187 (85.8)

308 (83.7)

0.501

 Weight, kg, mean (SD)

29.67 ± 12.51

28,15 ± 21.02

0.075

66.75 ± 9.59

66.01 ± 11.54

0.290

 BMI, mean (SD)

19.29 ± 4.39

18.35 ± 4.85

0.276

23.65 ± 3.20

23.37 ± 4.06

0.068

 History of hypertension, n (%)

0

1(0.9)

1.000

58 (26.6)

88 (23.9)

0.466

 History of diabetes, n (%)

0

0

1.000

12 (5.5)

21 (5.7)

0.918

Cause of death, n (%)

  

 < 0.01

  

0.048

 Trauma

27 (65.9)

46 (40.7)

 

78 (35.8)

124 (33.7)

 

 Cerebrovascular accident

14 (34.1)

37 (32.7)

 

136 (62.4)

221 (60.1)

 

 Other

0

30 (26.5)

 

4 (1.8)

23 (6.2)

 

By KDIGO stage, n (%)

  

 < 0.01

  

 < 0.01

 Stage 1

17 (41.5)

NA

 

86 (39.4)

NA

 

 Stage 2

13 (31.7)

NA

 

80 (36.7)

NA

 

 Stage 3

11 (26.8)

NA

 

52 (23.9)

NA

 

SCr, µmol/L, median (IQR)

      

 At admission

39.29 (30.10–59.90)

41.00 (30.50–66.40)

0.678

71.40 (58.20–87.70)

70.60 (56.15–88.00)

0.293

 Terminal

89.50 (63.80–148.30)

40.20 (26.07–54.00)

 < 0.01

163.45 (114.85–213.75)

71.20 (53.55–88.00)

 < 0.01

GFR, mL/min*1.73 m2, median (IQR)

     

 At admission

178.24 (134.26–187.05)

167.14 (136.48–193.76)

0.066

109.54 (85.54–118.09)

108.87 (87.91–121.61)

0.675

 Terminal

89.53 (52.65–140.18)

172.86 (149.54–209.07)

 < 0.01

40.00 (29.21–61.80)

105.32 (86.65–120.53)

 < 0.01

Recipients

      

 Age, years, mean (SD)

35.93 ± 12.38

33.72 ± 13.19

0.387

39.46 ± 10.31

39.85 ± 10.21

0.549

 Male, n (%)

28 (68.3)

71 (62.8)

0.573

161 (73.9)

267 (72.6)

0.732

 BMI, mean (SD)

21.53 ± 3.04

21.97 ± 11.59

0.063

22.43 ± 3.98

22.54 ± 3.52

0.590

 Diabetes, n (%)

0

3 (2.7)

0.565

16 (7.3)

26 (7.1)

0.901

 Hypertension, n (%)

31 (75.6)

96 (85.0)

0.178

188 (86.2)

232 (87.8)

0.591

 Days on dialysis, years, mean (SD)

1.44 ± 1.46

1.93 ± 2.81

0.822

2.11 ± 1.89

2.00 ± 2.14

0.074

Cause of ESRD, n (%)

  

0.322

  

0.179

 Diabetes

0 (0)

2 (1.8)

 

10 (4.6)

13 (3.5)

 

 Glomerulonephritis

38 (92.7)

105 (92.9)

 

186 (85.3)

332 (90.2)

 

 Hypertension

0

3 (2.7)

 

17 (7.8)

14 (3.8)

 

 Other

3 (7.3)

3 (2.7)

 

5 (2.3)

9 (2.4)

 

Transplant

      

 WIT, min, mean (SD)

3.94 ± 14.15

1.45 ± 3.07

0.291

1.96 ± 4.51

1.99 ± 5.04

0.686

 CIT, hours, mean (SD)

10.29 ± 3.11

10.92 ± 3.77

0.401

10.45 ± 2.97

10.66 ± 3.30

0.056

 PRA I ≥ 20, n (%)

2 (4.9)

5 (4.4)

0.905

14 (6.4)

22 (6.0)

0.829

 PRA II ≥ 20, n (%)

2 (4.9)

7 (6.2)

0.758

4 (1.8)

12 (3.3)

0.306

 HLA mismatches, mean (SD)

1.68 ± 1.11

1.72 ± 0.93

0.907

1.61 ± 1.03

1.67 ± 1.00

0.522

Induction immunosuppression (n, %)

 

0.180

  

0.015

 Basiliximab

15 (36.6)

28 (24.8)

 

57 (26.1)

141 (38.3)

 

 ATG

23 (56.1)

66 (58.4)

 

128 (58.8)

180 (48.9)

 

 No-use

3 (7.3)

19 (16.8)

 

33 (15.1)

49 (13.3)

 
  1. BMI body mass index, WIT warn ischemia time, CIT cold ischemia time, PRA panel-reactive antibodies, HLA human leukocyte antigen, ATG anti-human T lymphocyte rabbit immunoglobulin, DGF delayed graft function, PNF primary nonfunction, SCr serum creatinine, eGFR estimated glomerular filtration rate, NA not applicable
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us